Background It was urgent and necessary to synthesize the evidence for vaccine
effectiveness (VE) against SARS-CoV-2 variants of concern (VOC). We conducted a …

Responsible for more than 4.9 million deaths so far, COVID-19, caused by SARS-CoV-2, is
instigating devastating effects on the global health care system whose impacts could be …

As novel SARS-CoV-2 variants with different patterns of spike protein mutations have
emerged, the susceptibility of these variants to neutralization by antibodies has been rapidly …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disclose the variants of
concern (VOC) including Alpha (B. 1.1. 7), Beta (B. 1.351), Gamma (P1), Delta (B. 1.617. 2) …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Gamma variant of
concern has spread rapidly across Brazil since late 2020, causing substantial infection and …

The COVID-19 pandemic has led the world to undertake the largest vaccination campaign in
human history. In record time, unprecedented scientific and governmental efforts have …

Multiple studies of vaccinated and convalescent cohorts have demonstrated that serum
neutralizing antibody (nAb) titers correlate with protection against coronavirus disease 2019 …

Abstract As of 25 January 2022, over 349 million individuals have received a confirmed
diagnosis of covid-19, with over 5.59 million confirmed deaths associated with the SARS …

Background Different forms of vaccines have been developed to prevent the SARS‐CoV‐2
virus and subsequent COVID‐19 disease. Several are in widespread use globally …

Designing and manufacturing efficient vaccines against coronavirus disease 2019 (COVID‐
19) is a major objective. In this systematic review, we aimed to evaluate the most important …